Large-cap health care company Moderna has moved 4.3% this afternoon, reaching $113.31 per share. In contrast, the average analyst target price for the stock is $168.76.
Moderna, Inc., a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. The company is based in the United States.
Make Sure to Consider the Following Before Buying Moderna:
-
Moderna has moved -17.0% over the last year.
-
MRNA has a forward P/E ratio of -22.8 based on its EPS guidance of -4.97.
-
Over the last 5 years, earnings per share (EPS) have been growing at a compounded average rate of 9.4%.
-
The company has a price to earnings growth (PEG) ratio of 0.61.
-
Its Price to Book (P/B) ratio is 2.55
Moderna Has Irregular Cash Flows
| Date Reported | Cash Flow from Operations ($ k) | Capital expenditures ($ k) | Free Cash Flow ($ k) | YoY Growth (%) |
|---|---|---|---|---|
| 2023-02-24 | 4,981,000 | -400,000 | 5,381,000 | -61.3 |
| 2022-02-25 | 13,620,000 | -284,000 | 13,904,000 | 563.68 |
| 2021-02-26 | 2,027,000 | -68,000 | 2,095,000 | 590.63 |
| 2020-02-27 | -459,000 | -32,000 | -427,000 | -89.69 |
| 2019-02-06 | -330,865 | -105,766 | -225,099 |
Moderna's free cash flows have a decent average of $4.15 Billion over the last 5 years, but they are highly variable since their coefficient of variability is 2958439515.2%. The compounded average growth rate over this period is 0.0%.
